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Serologic determination of cytomegalovirus (CMV) infection status in organ donors and recipients is critical in stratifying the risk of CMV disease, a major cause of morbidity in solid-organ transplant (SOT) recipients [1] . However, false-positive serology results can occur due to passive antibodies, from transfusion or following transplacental transfer of maternal antibodies in infants of CMV-seropositive mothers.
Current guidelines suggest assuming the highest risk donor/ recipient CMV scenario for children up to 12 or 18 months of age in whom CMV serology may be unreliable [1, 2] . This results in unnecessary use of antivirals and/or monitoring, with resulting adverse effects and additional costs. Alternative methods to assign CMV infection status, not confounded by passive antibodies, are needed.
Direct detection of CMV DNA in urine or oropharyngeal secretions with nucleic acid amplification testing (NAAT) confirms CMV infection but the sensitivity of NAAT in assigning pretransplant CMV infection status has not been systematically evaluated [3] . Detection of stimulation-induced CMV-specific CD4 + T cells (CMV-TC) has shown promising results in assignment of CMV infection status in adults and healthy children, but has not been evaluated in children awaiting SOT [4] [5] [6] . As the majority of CMV-TC have an end-differentiated phenotype characterized by the loss of expression of the costimulatory receptors CD27 and CD28 on CD4 + T cells, after repeated cycles of antigenic stimulation, the frequency of CD27 
CD4
+ T cells correlates well with CMV seropositivity in adults, but has not been investigated in children [7, 8] .
We aimed to evaluate the use of 3 assays (CMV NAAT, flow cytometry-based detection of CMV-specific CD4 + T cells (CMV-TC assay), and CD27
+ T-cell analysis) to improve assignment of CMV infection status in children awaiting SOT, particularly in those whose infection status may be obscured by passive antibodies.
METHODS

Patients and Samples
Following approval from the University of Alberta Health Research Ethics Board (Pro0042807), we enrolled pediatric subjects awaiting SOT at the Stollery Children's Hospital (Edmonton, Canada) and age-matched (±2 years) controls undergoing cardiac catheterization. Informed consent/assent was obtained. Collection of a throat swab, and samples of saliva, urine, and blood was attempted in all participants. Saliva samples were collected by sterile water gargle in older children, and with Versi.SAL® 1 Saliva Collection Device in young children.
Detection of CMV DNA and Serology
CMV DNA was detected and quantified directly in throat, saliva, urine, and whole blood using our in-house-developed real-time polymerase chain reaction assay (assay conversion factor is 5.65 genome copies/mL = 1 IU/mL) [9] . Results >500 copies/mL (2.7 log10 copies/mL) were considered positive. CMV IgG antibodies were detected by enzyme immunoassay (Siemens Enzygnost Anti-CMV/IgG, Siemens Healthcare Diagnostics Products, Marburg, Germany).
Detection of CMV-TC
CMV-TC were identified from whole blood after 6-hour stimulation with CMV-antigen lysate via intracellular cytokine staining for interferon-gamma (IFN-γ)-fluorescein isothiocyanate and activation marker CD69-perCP expression using flow cytometry, as previously described [4] [5] [6] 10] Peripheral blood mononuclear cells were surface stained for CD4-V450, CD28-PerCP-Cy5.5 and CD27-APC-EF780, and fluorescence-activated cell sorting (FACS) analyzed on a BD FACSCanto. Samples were excluded if PI viability was <80%.
Data Analysis
CMV-seropositive individuals were considered to have potential passive antibodies if they were ≤18 months old and/or had received transfusion(s) of red cells, plasma, platelets, cryoprecipitate, whole blood, or intravenous immunoglobulin within the preceding 2 months. In children with potential passive antibodies, we used a combination of CMV serology and CMV NAAT to classify CMV infection status as (1) reliable or (2) unresolved; CMV infection status was considered reliably positive if CMV NAAT was positive; otherwise infection status was considered unresolved. CMV infection status was considered reliably positive in CMV-seropositive children without potential passive antibodies and reliably negative in CMVseronegative children. (Supplementary Figure 1) .
FACS analysis was performed blinded to CMV serology and NAAT results using FlowJo (FlowJo, Ashland, OR) software. Gates were placed as quadrants based on the respective negative controls of each individual and not modified based on visual appearance of distinct populations.
Statistical analysis was performed as described in the Supplementary Methods.
RESULTS
We enrolled 25 subjects awaiting SOT (6 kidney, 11 liver, 2 lung, 6 heart) and 25 controls (Supplementary Table 1 ) who were similar with respect to median age (subjects 1.86 years, controls 2.59 years.), gender (52% male subjects and controls), and CMV-seropositivity (40% subjects, 28% controls). The proportion with thymectomy, from previous cardiac surgery, was significantly higher among controls than subjects (52% vs 12%, P = .005).
Detection of CMV DNA by NAAT
All children had blood and throat swabs collected, 49/50 had urine and 41/50 had saliva samples. Saliva collection was unsuccessful in 9 children due to insufficient saliva to saturate the collection device or child refusal of the device. CMV NAAT was positive in at least 1 specimen in 8/17 (47.1%) CMV-seropositive children and confirmed positive infection status in 6/11 (54.6%) seropositive children with potential passive antibodies ( Figure 1 and Supplementary Table 2) . No CMV-seronegative child had a positive CMV NAAT result.
CMV-TC Assay and CD27
−
28
− CD4 + T cells
Results for CMV-TC assay and CD27 − CD28 − CD4 + T-cell analysis were available for 47/50 and 45/50 children, respectively. Two control samples with poor cell viability were excluded from both assays. Three samples were excluded for technical reasons, 1 from both assays (subject) and 2 from CD27 Frequency of CMV-TC by CMV serostatus are presented in Figure 2 . In children with reliable positive infection status, frequency of CMV-TC was similar in children with and without thymectomy (P = .85). Receiver operating characteristic (ROC) analysis using CMV-TC results from children with reliable infection status (10 seropositive, 31 seronegative), determined that a cutoff of 0.035% CMV-TC distinguished CMV-seropositive from seronegative children with reliable infection status with a sensitivity of 80% and specificity of 94% (area under the curve
[AUC] 0.87) (Supplementary Table 3) . Figure 2B highlights that, among those with reliable positive infection status, all 5 children >18 months of age had detectable CMV-TC but only 3/5 children <18 months had detectable CMV-TC. Two of 31 seronegative children, controls aged 3 and 11 years, had detectable CMV-TC. Figure 2C illustrates A, The CMV-TC assay yielded valid results in 45/50 children; 2 subjects (aged 0.96 and 4 years) had indeterminate results, due to high background reactivity, and were excluded from analysis. CMV-TC frequencies are similar between CMV-seropositive controls and subjects with reliable infection status (adjusted P = 1.0) and between CMV-seronegative controls and subjects (adjusted P = 1.0). There was no significant difference in CMV-TC frequencies between CMV-seropositive controls with reliable infection status and CMV-seronegative controls (adjusted P = .088). *adjusted P = .0032. B, CMV-TC by age in CMV-seropositive children. Of 5 CMV-seropositive children <18 months with positive CMV nucleic acid amplification testing (NAAT), 3 had detectable CMV-TC. None of the 4 CMV-seropositive children <18 months with negative CMV NAAT (unresolved infection status) had detectable CMV-TC. The 0-18 month portion of the graph is magnified in the upper left corner for easier interpretation. C, CD27 − CD28 − CD4 + T-cell frequencies were similar between CMV-seropositive controls and subjects with reliable infection status (adjusted P = .27) and between CMV-seronegative controls and subjects (adjusted P = .79). There was no significant difference in CD27 − CD28 − CD4 + T-cell frequencies between CMV-seropositive subjects with reliable infection status and CMV-seronegative subjects (adjusted P = .66). **adjusted P = .026. D, Children of all ages were misclassified using either of the 2 potential cutoffs of CD27 + T-cell frequencies were significantly higher in children with a history of thymectomy compared with those without (P = .028, P = .023) (Supplementary Figure 2) . Median age was similar between children with and without thymectomy (2. Table 4 ). Given the differences in CD27 − CD28 − CD4 + T-cell frequencies between children with and without thymectomy, we repeated ROC analyses excluding children with thymectomy; a lower cutoff of 0.70% distinguished CMV-seropositive from seronegative children with reliable infection status, with sensitivity and specificity of 71% (AUC 0.71). Issues with sensitivity and specificity existed across all ages regardless of which of the 2 cutoff values was used to distinguish CMV-seropositive from seronegative children ( Figure 2D ). Figure 1 illustrates the results of CMV NAAT, CMV-TC assay, and CD27
+ T-cell frequencies in seropositive children with potential passive antibodies.
DISCUSSION
This study confirms that detection of CMV DNA from urine and oropharyngeal samples is common in CMV-seropositive children and that CMV NAAT is a useful adjunct to serology where it confirmed positive infection status in 5 of 10 seropositive children <18 months old.
Using the CMV-TC assay from which our assay was adapted and a cutoff of 0.05% CMV-TC, Ritter and colleagues found perfect agreement between CMV serology and detection of CMV-TC in children >18 months [6] . Using a lower detection limit of 0.035%, we detected CMV-TC in all children >18 months with reliable positive infection status. We detected CMV-TC in 2 CMV-seronegative children; this has been described in adults with the suggestion that the presence of CMV-TC may be more useful than serology in predicting the recipient's ability to control CMV posttransplant [5, 11] . In Ritter's study of 13 CMV-seropositive children <18 months, 8 had detectable CMV-TC and the other 5 were presumed to have passive maternal antibody, but viral shedding was not studied [6] . We were unable to detect CMV-TC in 2/5 CMV-seropositive children <18 months with positive CMV NAAT results. This may indicate recent infection, where CMV IgG may still be passive, as adaptive immunity has not yet been induced. Alternatively, lack of detectable T cells may be due to immaturity of the T-cell response to CMV in early childhood, which has been documented in previous studies with congenital and postnatally acquired CMV [12, 13] . Thus, while the presence of CMV-DNA or CMV-TC supports positive infection status, the absence of detectable DNA or CMV-TC is not reliable evidence of true negative infection status in seropositive young children. The variability in CD4 + T-cell response to primary CMV infection in young children limits the use of CMV-TC analysis, at least on its own, as an alternative to serology in children with potential passive antibodies. However, the combination of CMV NAAT and CMV-TC may identify children at particularly high risk of CMV-related complications posttransplant, children with poor immune control of CMV with positive NAAT without detectable CMV-TC, and children who may be at lower risk (those with positive NAAT and detectable CMV-TC).
Compared to stimulation-based CMV-TC assays, determination of CD27 + T cells discriminated between CMV-seropositive and seronegative individuals, with 93% sensitivity and 97% specificity [8] . We found that frequency of CD27 − CD28 − CD4 + T cells had lower sensitivity and specificity in defining CMV status in children, perhaps because of differences in immune responses and the fact that children are more likely to have recent primary infection. As these cells are of an end-differentiated phenotype, it was surprising that many children in our study, CMV-seropositive and seronegative, had CD27 − CD28 − CD4 + T-cell frequencies above the 0.44% cutoff established in adults. This may be attributed to previous thymectomy in some children. Prior studies have documented a decreased proportion of naive CD4 + T cells and an increased proportion of highly differentiated memory T cells in children and young adults with thymectomy in infancy [14, 15] . Inclusion of children with thymectomy may have made it less likely for us to detect significant differences in CD27 − CD28 − CD4 + T-cell frequencies between CMV-seropositive and seronegative children. However, even after excluding children with thymectomy, the frequency of CD27 − CD28 − CD4 + T cells was not a reliable marker of CMV infection status.
Limitations of the study are that it was performed in a single institution in a developed country where CMV seroprevalence in children >12 months is likely <30%, with a small sample size. Completely healthy controls would have been ideal but could require unnecessary blood draws from children.
Our study highlights that saliva and urine samples for CMV NAAT should routinely be obtained from CMV-seropositive children <18 months of age awaiting SOT as, when positive, they confirm positive infection status. The CMV-TC assay lacks sensitivity in identifying positive CMV infection status in children <12 months but may prove useful in combination with CMV NAAT to identify CMV-infected children with poor immune control of CMV, who may be at higher risk for symptomatic donor-acquired CMV infection. CD27 − CD28 − CD4
+ T-cell analysis is unlikely to be useful in establishing CMV infection status in children but clarifies aspects of premature aging of the immune system in the context of thymectomy.
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